Evidence map›Paper›PMID 37819998›Full record

ArticleImmunoHorizons2023

Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity.

Vanessa Silva-Moraes, Aisha Souquette, Giuseppe A Sautto, Ida Paciello, Giada Antonelli, Emanuele Andreano, Rino Rappuoli, Andréa Teixeira-Carvalho, Ted M Ross

Open access · goldAbstract read
In one paragraph

Article in ImmunoHorizons, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Avidity maturation of anti-spike IgG after vaccination in COVID-19 convalescent vs COVID-19 naïve patients.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Vanessa Silva-MoraesCenter for Vaccines and Immunology, University of Georgia, Athens, GA.ORCID 0000-0003-2991-7210
Aisha SouquetteDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-6197-5870
Giuseppe A SauttoCenter for Vaccines and Immunology, University of Georgia, Athens, GA.ORCID 0000-0002-0273-2235
Ida PacielloMonoclonal Antibody Discovery Lab, Foundation Toscana Life Sciences, Siena, Italy.
Giada AntonelliMonoclonal Antibody Discovery Lab, Foundation Toscana Life Sciences, Siena, Italy.ORCID 0000-0003-1065-6866
Emanuele AndreanoMonoclonal Antibody Discovery Lab, Foundation Toscana Life Sciences, Siena, Italy.
Rino RappuoliFondazione Biotecnopolo di Siena, Siena, Italy.ORCID 0000-0002-8827-254X
Andréa Teixeira-CarvalhoIntegrated Research Group in Biomarkers, René Rachou Institute-FIOCRUZ, Belo Horizonte, Brazil.
Ted M RossCenter for Vaccines and Immunology, University of Georgia, Athens, GA.ORCID 0000-0003-1947-7469
Cleveland Clinic · USToscana Life Sciences · ITFundação Oswaldo Cruz · BRSt. Jude Children's Research Hospital · US

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
NIAID NIH HHS 75N93019C00052
6 · The paper itself

Abstract

Spike-encoding mRNA vaccines in early 2021 effectively reduced SARS-CoV-2-associated morbidity and mortality. New booster regimens were introduced due to successive waves of distinct viral variants. Therefore, people now have a diverse immune memory resulting from multiple SARS-CoV-2 Ag exposures, from infection to following vaccination. This level of community-wide immunity can induce immunological protection from SARS-CoV-2; however, questions about the trajectory of the adaptive immune responses and long-term immunity with respect to priming and repeated Ag exposure remain poorly explored. In this study, we examined the trajectory of adaptive immune responses following three doses of monovalent Pfizer BNT162b2 mRNA vaccination in immunologically naive and SARS-CoV-2 preimmune individuals without the occurrence of breakthrough infection. The IgG, B cell, and T cell Spike-specific responses were assessed in human blood samples collected at six time points between a moment before vaccination and up to 6 mo after the third immunization. Overall, the impact of repeated Spike exposures had a lower improvement on T cell frequency and longevity compared with IgG responses. Natural infection shaped the responses following the initial vaccination by significantly increasing neutralizing Abs and specific CD4+ T cell subsets (circulating T follicular helper, effector memory, and Th1-producing cells), but it had a small benefit at long-term immunity. At the end of the three-dose vaccination regimen, both SARS-CoV-2-naive and preimmune individuals had similar immune memory quality and quantity. This study provides insights into the durability of mRNA vaccine-induced immunological memory and the effects of preimmunity on long-term responses.

Indexed as

BNT162 VaccineCOVID-19mRNA VaccinesHumansImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GLymphocyte SubsetsSARS-CoV-2Vaccine EfficacyVaccines, SyntheticBNT162 VaccineImmunoglobulin GmRNA VaccinesVaccines, Synthetic

Identifiers

PMID37819998
PMCPMC10615651
OpenAlexW4387526733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.